Clinical Trials Browser

Sunitinib × Endocrine × Clear all

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00381641 2025-03-28

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Phase 2 Completed

63 enrolled 12 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT02282059 2024-06-20

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

100 enrolled 13 charts

EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT01371201 2022-08-04

FIRSTMAPPP

Phase 2 Completed

Paraganglioma

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2 Terminated

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00668811 2020-08-05

IIT Sutent

Phase 2 Completed

23 enrolled 7 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02713763 2020-03-04

RESUNET

Phase 2 Completed

EndocrineGastrointestinal

Pancreatic Neuroendocrine Tumour Metastatic

NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Phase 4 Completed

106 enrolled 26 charts

EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

NCT00519896 2017-04-25

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Phase 2 Completed

35 enrolled 8 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT01731925 2017-01-31

SUNLAND

Phase 2 Unknown

Carcinoid Tumor, Neoplasm Metastasis

NCT01215578 2015-04-30

NET

Phase 2 Terminated

EndocrineGastrointestinalNET

Adenocarcinoma, Adenoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT01121562 2014-06-30

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Phase 2 Completed

12 enrolled 9 charts

Neuroendocrine Tumors

NCT00434109 2012-09-14

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Phase 2 Completed

39 enrolled 11 charts

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT00056693 2008-07-21

Treatment With SU11248 in Patients With Neuroendocrine Tumors

Phase 2 Completed

Neuroendocrine Tumors